1
|
Lu JS, Cao AC, Shimunov D, Sun L, Lukens JN, Lin A, Cohen RB, Basu D, Cannady SB, Rajasekaran K, Weinstein GS, Brody RM. Functional Outcomes in Patients with Human Papillomavirus-Associated Oropharyngeal Squamous Cell Cancer Treated with Trimodality Therapy. Laryngoscope 2023; 133:3013-3020. [PMID: 37129315 DOI: 10.1002/lary.30714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Revised: 03/22/2023] [Accepted: 03/30/2023] [Indexed: 05/03/2023]
Abstract
OBJECTIVES To describe swallowing and feeding-tube outcomes in patients with high-risk oropharyngeal cancer treated with trimodality therapy (TMT), including transoral robotic surgery (TORS) and adjuvant chemoradiotherapy. METHODS A chart review was conducted on patients with HPV+ OPSCC receiving TMT with TORS at an academic medical center from March 2010 to March 2021. Data collected included demographics, treatment, feeding tube placement, functional oral intake scale (FOIS) scores, and swallowing-language pathology (SLP) evaluations. RESULTS A total of 255 patients met selection criteria (mean age 61 years, 88% male). Following intraoperative nasogastric tube (NG) placement, 31% remained NG tube dependent after 3 weeks. A gastrostomy tube was placed in 19% of patients, and at 1 year after end-of-treatment (EOT), 3.5% overall remained tube-dependent. Mean FOIS scores were 6.9 (SD = 0.3) at pre-operative visit, 2.6 (1.8) at first post-operative visit, and 5.5 (1.5) after EOT. In the subset of patients with follow-up longer than 2 years (n = 118), the mean FOIS was 6.1 (SD = 1.3) at most recent visit. Clinical signs of aspiration/penetration were suspected on SLP evaluation in 18% of patients. These patients were subsequently evaluated with fiberoptic endoscopic evaluation of swallowing (FEES) and/or barium swallow study, which confirmed signs of aspiration in 2.7% of patients overall. Delayed NG tube removal after 3 weeks was predictive of (1) gastrostomy tube requirement and (2) clinical signs of aspiration on an SLP visit after EOT. CONCLUSIONS Favorable functional and feeding-tube outcomes are demonstrated in patients with HPV-associated OPSCC undergoing TMT. In this single-institution study, we found low rates of long-term feeding tube dependence and high median FOIS following treatment. Review of routine SLP visits provides a detailed and easily accessible means for assessing swallowing function in this cohort. LEVEL OF EVIDENCE 4 Laryngoscope, 133:3013-3020, 2023.
Collapse
Affiliation(s)
- Joseph S Lu
- Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
- Department of Otorhinolaryngology - Head and Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Austin C Cao
- Department of Otorhinolaryngology - Head and Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - David Shimunov
- Department of Otorhinolaryngology - Head and Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Lova Sun
- Department of Medicine - Medical Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - John N Lukens
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Alexander Lin
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Roger B Cohen
- Department of Medicine - Medical Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Devraj Basu
- Department of Otorhinolaryngology - Head and Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Steven B Cannady
- Department of Otorhinolaryngology - Head and Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Karthik Rajasekaran
- Department of Otorhinolaryngology - Head and Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Gregory S Weinstein
- Department of Otorhinolaryngology - Head and Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Robert M Brody
- Department of Otorhinolaryngology - Head and Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| |
Collapse
|
2
|
Choby G, Geltzeiler M, Almeida JP, Champagne PO, Chan E, Ciporen J, Chaskes MB, Fernandez-Miranda J, Gardner P, Hwang P, Ji KSY, Kalyvas A, Kong KA, McMillan R, Nayak J, O’Byrne J, Patel C, Patel Z, Peris Celda M, Pinheiro-Neto C, Sanusi O, Snyderman C, Thorp BD, Van Gompel JJ, Young SC, Zenonos G, Zwagerman NT, Wang EW. Multicenter Survival Analysis and Application of an Olfactory Neuroblastoma Staging Modification Incorporating Hyams Grade. JAMA Otolaryngol Head Neck Surg 2023; 149:837-844. [PMID: 37535372 PMCID: PMC10401389 DOI: 10.1001/jamaoto.2023.1939] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2023] [Accepted: 06/08/2023] [Indexed: 08/04/2023]
Abstract
Importance Current olfactory neuroblastoma (ONB) staging systems inadequately delineate locally advanced tumors, do not incorporate tumor grade, and poorly estimate survival and recurrence. Objective The primary aims of this study were to (1) examine the clinical covariates associated with survival and recurrence of ONB in a modern-era multicenter cohort and (2) incorporate Hyams tumor grade into existing staging systems to assess its ability to estimate survival and recurrence. Design, Setting, and Participants This retrospective, multicenter, case-control study included patients with ONB who underwent treatment between January 1, 2005, and December 31, 2021, at 9 North American academic medical centers. Intervention Standard-of-care ONB treatment. Main Outcome and Measures The main outcomes were overall survival (OS), disease-free survival (DFS), and disease-specific survival (DSS) as C statistics for model prediction. Results A total of 256 patients with ONB (mean [SD] age, 52.0 [15.6] years; 115 female [44.9%]; 141 male [55.1%]) were included. The 5-year rate for OS was 83.5% (95% CI, 78.3%-89.1%); for DFS, 70.8% (95% CI, 64.3%-78.0%); and for DSS, 94.1% (95% CI, 90.5%-97.8%). On multivariable analysis, age, American Joint Committee on Cancer (AJCC) stage, involvement of bilateral maxillary sinuses, and positive margins were associated with OS. Only AJCC stage was associated with DFS. Only N stage was associated with DSS. When assessing the ability of staging systems to estimate OS, the best-performing model was the novel modification of the Dulguerov system (C statistic, 0.66; 95% CI, 0.59-0.76), and the Kadish system performed most poorly (C statistic, 0.57; 95% CI, 0.50-0.63). Regarding estimation of DFS, the modified Kadish system performed most poorly (C statistic, 0.55; 95% CI, 0.51-0.66), while the novel modification of the AJCC system performed the best (C statistic, 0.70; 95% CI, 0.66-0.80). Regarding estimation of DSS, the modified Kadish system was the best-performing model (C statistic, 0.79; 95% CI, 0.70-0.94), and the unmodified Kadish performed the worst (C statistic, 0.56; 95% CI, 0.51-0.68). The ability for novel ONB staging systems to estimate disease progression across stages was also assessed. In the novel Kadish staging system, patients with stage VI disease were approximately 7 times as likely to experience disease progression as patients with stage I disease (hazard ratio [HR], 6.84; 95% CI, 1.60-29.20). Results were similar for the novel modified Kadish system (HR, 8.99; 95% CI, 1.62-49.85) and the novel Dulguerov system (HR, 6.86; 95% CI, 2.74-17.18). Conclusions and Relevance The study findings indicate that 5-year OS for ONB is favorable and that incorporation of Hyams grade into traditional ONB staging systems is associated with improved estimation of disease progression.
Collapse
Affiliation(s)
- Garret Choby
- Department of Otolaryngology–Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota
| | - Mathew Geltzeiler
- Department of Otolaryngology–Head and Neck Surgery, Oregon Health & Science University, Portland, Oregon
| | | | | | - Erik Chan
- Department of Otolaryngology–Head and Neck Surgery, Stanford University, Palo Alto, California
| | - Jeremy Ciporen
- Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon
| | - Mark B. Chaskes
- Department of Otolaryngology–Head and Neck Surgery, University of North Carolina at Chapel Hill
| | | | - Paul Gardner
- Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
| | - Peter Hwang
- Department of Otolaryngology–Head and Neck Surgery, Stanford University, Palo Alto, California
| | - Keven Seung Yong Ji
- Department of Otolaryngology–Head and Neck Surgery, Oregon Health & Science University, Portland, Oregon
| | | | - Keonho A. Kong
- Department of Otolaryngology–Head and Neck Surgery, University of North Carolina at Chapel Hill
| | - Ryan McMillan
- Department of Otolaryngology–Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota
| | - Jayakar Nayak
- Department of Otolaryngology–Head and Neck Surgery, Stanford University, Palo Alto, California
| | - Jamie O’Byrne
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota
| | - Chirag Patel
- Department of Otolaryngology–Head and Neck Surgery, Loyola University, Maywood, Illinois
| | - Zara Patel
- Department of Otolaryngology–Head and Neck Surgery, Stanford University, Palo Alto, California
| | - Maria Peris Celda
- Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota
| | - Carlos Pinheiro-Neto
- Department of Otolaryngology–Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota
| | - Olabisi Sanusi
- Department of Otolaryngology–Head and Neck Surgery, University of North Carolina at Chapel Hill
| | - Carl Snyderman
- Department of Otolaryngology–Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
| | - Brian D. Thorp
- Department of Otolaryngology–Head and Neck Surgery, University of North Carolina at Chapel Hill
| | | | - Sarah C. Young
- Department of Neurological Surgery, University of Wisconsin, Milwaukee, Wisconsin
| | - Georgios Zenonos
- Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
| | - Nathan T. Zwagerman
- Department of Neurological Surgery, University of Wisconsin, Milwaukee, Wisconsin
| | - Eric W. Wang
- Department of Otolaryngology–Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
| |
Collapse
|
3
|
Anzai Y, Chang CP, Rowe K, Snyder J, Deshmukh V, Newman M, Fraser A, Smith K, Date A, Galvao C, Monroe M, Hashibe M. Surveillance Imaging with PET/CT and CT and/or MRI for Head and Neck Cancer and Mortality: A Population-based Study. Radiology 2023; 307:e212915. [PMID: 36625743 PMCID: PMC10102644 DOI: 10.1148/radiol.212915] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2021] [Revised: 08/21/2022] [Accepted: 11/09/2022] [Indexed: 01/11/2023]
Abstract
Background To the knowledge of the authors, no strong evidence supports surveillance imaging in patients with head and neck cancer (HNC). Purpose To investigate the association between surveillance imaging and mortality using a population-based study design with statewide cancer registry data, all-payer claims data, and health care facility data. Materials and Methods The retrospective population-based study identified patients with HNC diagnosed between January 2012 and December 2017. Current Procedural Terminology codes were used to search surveillance imaging procedures. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% CIs for mortality with adjustment for sex, ethnicity, age, health insurance status, cancer site, stage, and treatment. Results The study identified 1004 patients (mean age, 61 years ± 12 [SD]; 753 men), including 902 patients with squamous cell carcinoma (SCC) HNC and 102 patients with non-SCC. The effect of imaging on mortality among patients with SCC was not statistically significant when the entire sample was analyzed (HR, 0.76; 95% CI: 0.57, 1.02; P = .07). However, in stratified analyses by cancer stage, surveillance imaging was associated with lower mortality among patients with SCC for regionalized cancer stage (HR, 0.55; 95% CI: 0.36, 0.83; P = .005) and distant cancer stage (HR, 0.40; 95% CI: 0.19, 0.83; P = .01). Among patients with non-SCC, surveillance imaging was associated with lower mortality versus no surveillance imaging (HR, 0.19; 95% CI: 0.04, 0.94; P = .04). PET/CT was associated with lower mortality for patients with SCC (HR, 0.29; 95% CI: 0.09, 0.94; P = .04), and CT and/or MRI was associated with lower mortality for patients with non-SCC (HR, 0.11; 95% CI: 0.01, 0.94; P = .04). Conclusion Surveillance imaging was associated with lower mortality among patients with head and neck squamous cell carcinoma with regionalized or distant disease. The surveillance imaging protective association was observed up to 2 years after treatment completion. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Branstetter in this issue.
Collapse
Affiliation(s)
- Yoshimi Anzai
- From the Huntsman Cancer Institute, Salt Lake City, Utah (Y.A.,
C.P.C., M.H.); Division of Public Health, Department of Family &
Preventive Medicine (C.P.C., M.H.), Division of Otolaryngology, Department of
Surgery (M.M.), and Department of Radiology and Imaging Sciences (Y.A.),
University of Utah School of Medicine, 30N 1900 E, IA 71, Salt Lake City, UT
84102; Intermountain Healthcare, Salt Lake City, Utah (K.R., J.S.); University
of Utah Health Sciences Center, Salt Lake City, Utah (V.D., M.N.); and Pedigree
and Population Resource, Population Sciences, Huntsman Cancer Institute, Salt
Lake City, Utah (A.F., K.S., A.D., C.G.)
| | - Chun-Pin Chang
- From the Huntsman Cancer Institute, Salt Lake City, Utah (Y.A.,
C.P.C., M.H.); Division of Public Health, Department of Family &
Preventive Medicine (C.P.C., M.H.), Division of Otolaryngology, Department of
Surgery (M.M.), and Department of Radiology and Imaging Sciences (Y.A.),
University of Utah School of Medicine, 30N 1900 E, IA 71, Salt Lake City, UT
84102; Intermountain Healthcare, Salt Lake City, Utah (K.R., J.S.); University
of Utah Health Sciences Center, Salt Lake City, Utah (V.D., M.N.); and Pedigree
and Population Resource, Population Sciences, Huntsman Cancer Institute, Salt
Lake City, Utah (A.F., K.S., A.D., C.G.)
| | - Kerry Rowe
- From the Huntsman Cancer Institute, Salt Lake City, Utah (Y.A.,
C.P.C., M.H.); Division of Public Health, Department of Family &
Preventive Medicine (C.P.C., M.H.), Division of Otolaryngology, Department of
Surgery (M.M.), and Department of Radiology and Imaging Sciences (Y.A.),
University of Utah School of Medicine, 30N 1900 E, IA 71, Salt Lake City, UT
84102; Intermountain Healthcare, Salt Lake City, Utah (K.R., J.S.); University
of Utah Health Sciences Center, Salt Lake City, Utah (V.D., M.N.); and Pedigree
and Population Resource, Population Sciences, Huntsman Cancer Institute, Salt
Lake City, Utah (A.F., K.S., A.D., C.G.)
| | - John Snyder
- From the Huntsman Cancer Institute, Salt Lake City, Utah (Y.A.,
C.P.C., M.H.); Division of Public Health, Department of Family &
Preventive Medicine (C.P.C., M.H.), Division of Otolaryngology, Department of
Surgery (M.M.), and Department of Radiology and Imaging Sciences (Y.A.),
University of Utah School of Medicine, 30N 1900 E, IA 71, Salt Lake City, UT
84102; Intermountain Healthcare, Salt Lake City, Utah (K.R., J.S.); University
of Utah Health Sciences Center, Salt Lake City, Utah (V.D., M.N.); and Pedigree
and Population Resource, Population Sciences, Huntsman Cancer Institute, Salt
Lake City, Utah (A.F., K.S., A.D., C.G.)
| | - Vikrant Deshmukh
- From the Huntsman Cancer Institute, Salt Lake City, Utah (Y.A.,
C.P.C., M.H.); Division of Public Health, Department of Family &
Preventive Medicine (C.P.C., M.H.), Division of Otolaryngology, Department of
Surgery (M.M.), and Department of Radiology and Imaging Sciences (Y.A.),
University of Utah School of Medicine, 30N 1900 E, IA 71, Salt Lake City, UT
84102; Intermountain Healthcare, Salt Lake City, Utah (K.R., J.S.); University
of Utah Health Sciences Center, Salt Lake City, Utah (V.D., M.N.); and Pedigree
and Population Resource, Population Sciences, Huntsman Cancer Institute, Salt
Lake City, Utah (A.F., K.S., A.D., C.G.)
| | - Michael Newman
- From the Huntsman Cancer Institute, Salt Lake City, Utah (Y.A.,
C.P.C., M.H.); Division of Public Health, Department of Family &
Preventive Medicine (C.P.C., M.H.), Division of Otolaryngology, Department of
Surgery (M.M.), and Department of Radiology and Imaging Sciences (Y.A.),
University of Utah School of Medicine, 30N 1900 E, IA 71, Salt Lake City, UT
84102; Intermountain Healthcare, Salt Lake City, Utah (K.R., J.S.); University
of Utah Health Sciences Center, Salt Lake City, Utah (V.D., M.N.); and Pedigree
and Population Resource, Population Sciences, Huntsman Cancer Institute, Salt
Lake City, Utah (A.F., K.S., A.D., C.G.)
| | - Alison Fraser
- From the Huntsman Cancer Institute, Salt Lake City, Utah (Y.A.,
C.P.C., M.H.); Division of Public Health, Department of Family &
Preventive Medicine (C.P.C., M.H.), Division of Otolaryngology, Department of
Surgery (M.M.), and Department of Radiology and Imaging Sciences (Y.A.),
University of Utah School of Medicine, 30N 1900 E, IA 71, Salt Lake City, UT
84102; Intermountain Healthcare, Salt Lake City, Utah (K.R., J.S.); University
of Utah Health Sciences Center, Salt Lake City, Utah (V.D., M.N.); and Pedigree
and Population Resource, Population Sciences, Huntsman Cancer Institute, Salt
Lake City, Utah (A.F., K.S., A.D., C.G.)
| | - Ken Smith
- From the Huntsman Cancer Institute, Salt Lake City, Utah (Y.A.,
C.P.C., M.H.); Division of Public Health, Department of Family &
Preventive Medicine (C.P.C., M.H.), Division of Otolaryngology, Department of
Surgery (M.M.), and Department of Radiology and Imaging Sciences (Y.A.),
University of Utah School of Medicine, 30N 1900 E, IA 71, Salt Lake City, UT
84102; Intermountain Healthcare, Salt Lake City, Utah (K.R., J.S.); University
of Utah Health Sciences Center, Salt Lake City, Utah (V.D., M.N.); and Pedigree
and Population Resource, Population Sciences, Huntsman Cancer Institute, Salt
Lake City, Utah (A.F., K.S., A.D., C.G.)
| | - Ankita Date
- From the Huntsman Cancer Institute, Salt Lake City, Utah (Y.A.,
C.P.C., M.H.); Division of Public Health, Department of Family &
Preventive Medicine (C.P.C., M.H.), Division of Otolaryngology, Department of
Surgery (M.M.), and Department of Radiology and Imaging Sciences (Y.A.),
University of Utah School of Medicine, 30N 1900 E, IA 71, Salt Lake City, UT
84102; Intermountain Healthcare, Salt Lake City, Utah (K.R., J.S.); University
of Utah Health Sciences Center, Salt Lake City, Utah (V.D., M.N.); and Pedigree
and Population Resource, Population Sciences, Huntsman Cancer Institute, Salt
Lake City, Utah (A.F., K.S., A.D., C.G.)
| | - Carlos Galvao
- From the Huntsman Cancer Institute, Salt Lake City, Utah (Y.A.,
C.P.C., M.H.); Division of Public Health, Department of Family &
Preventive Medicine (C.P.C., M.H.), Division of Otolaryngology, Department of
Surgery (M.M.), and Department of Radiology and Imaging Sciences (Y.A.),
University of Utah School of Medicine, 30N 1900 E, IA 71, Salt Lake City, UT
84102; Intermountain Healthcare, Salt Lake City, Utah (K.R., J.S.); University
of Utah Health Sciences Center, Salt Lake City, Utah (V.D., M.N.); and Pedigree
and Population Resource, Population Sciences, Huntsman Cancer Institute, Salt
Lake City, Utah (A.F., K.S., A.D., C.G.)
| | - Marcus Monroe
- From the Huntsman Cancer Institute, Salt Lake City, Utah (Y.A.,
C.P.C., M.H.); Division of Public Health, Department of Family &
Preventive Medicine (C.P.C., M.H.), Division of Otolaryngology, Department of
Surgery (M.M.), and Department of Radiology and Imaging Sciences (Y.A.),
University of Utah School of Medicine, 30N 1900 E, IA 71, Salt Lake City, UT
84102; Intermountain Healthcare, Salt Lake City, Utah (K.R., J.S.); University
of Utah Health Sciences Center, Salt Lake City, Utah (V.D., M.N.); and Pedigree
and Population Resource, Population Sciences, Huntsman Cancer Institute, Salt
Lake City, Utah (A.F., K.S., A.D., C.G.)
| | - Mia Hashibe
- From the Huntsman Cancer Institute, Salt Lake City, Utah (Y.A.,
C.P.C., M.H.); Division of Public Health, Department of Family &
Preventive Medicine (C.P.C., M.H.), Division of Otolaryngology, Department of
Surgery (M.M.), and Department of Radiology and Imaging Sciences (Y.A.),
University of Utah School of Medicine, 30N 1900 E, IA 71, Salt Lake City, UT
84102; Intermountain Healthcare, Salt Lake City, Utah (K.R., J.S.); University
of Utah Health Sciences Center, Salt Lake City, Utah (V.D., M.N.); and Pedigree
and Population Resource, Population Sciences, Huntsman Cancer Institute, Salt
Lake City, Utah (A.F., K.S., A.D., C.G.)
| |
Collapse
|
4
|
Houschyar KS, Borrelli MR, Rein S, Tapking C, Popp D, Palackic A, Puladi B, Ooms M, Houschyar M, Branski LK, Schmitt L, Modabber A, Rübben A, Hölzle F, Yazdi AS. Head and neck squamous cell carcinoma: a potential therapeutic target for the Wnt signaling pathway. EUROPEAN JOURNAL OF PLASTIC SURGERY 2022. [DOI: 10.1007/s00238-022-01958-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Abstract
Squamous cell carcinoma (SCC) of the head and neck region accounts for 3% of all tumors worldwide. The incidence is higher in men, with most carcinomas found in the oral cavity. At the point of initial diagnosis, distant metastases are rare. The Wnt signaling pathway is critically involved in cell development and stemness and has been associated with SCC. Understanding precisely how Wnt signaling regulates SCC progression and how it can, therefore, be modulated for the therapeutic benefit has enormous potential in the treatment of head and neck SCC. In this review, we will describe the underlying mechanisms of Wnt signaling and outline how Wnt signaling controls cellular processes both in homeostasis and in the development and progression of SCC.Level of evidence: Not gradable.
Collapse
|
5
|
PET Imaging of Oral Cavity and Oropharyngeal Cancers. PET Clin 2022; 17:223-234. [DOI: 10.1016/j.cpet.2021.12.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
6
|
Cai Y, Yang W. PKMYT1 regulates the proliferation and epithelial‑mesenchymal transition of oral squamous cell carcinoma cells by targeting CCNA2. Oncol Lett 2021; 23:63. [PMID: 35069872 PMCID: PMC8756561 DOI: 10.3892/ol.2021.13181] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2021] [Accepted: 11/08/2021] [Indexed: 12/24/2022] Open
Abstract
Oral squamous cell carcinoma (OSCC) has gradually become a global public health issue in recent years. Therefore, the current study aimed to explore the mechanism of OSCC development and to identify a potential target that may be used in its treatment. The expression of protein kinase, membrane-associated tyrosine/threonine 1 (PKMYT1) and cyclin A2 (CCNA2) in SCC-9 cells was determined prior to and following transfection with short hairpin RNA targeting PKMYT1. Cell proliferation, colony-forming ability, migration and invasion were determined using Cell Counting Kit-8, colony formation, wound healing and Transwell assays, respectively. Furthermore, the expression of epithelial-mesenchymal transition (EMT)- and migration-related proteins were evaluated using western blot analysis. Additionally, co-immunoprecipitation was used to verify the binding of PKMYT1 and CCNA2. The results revealed that PKMYT1 was highly expressed in OSCC cells and that PKMYT1 knockdown could inhibit proliferation, colony formation, migration, invasion, EMT and CCNA2 expression in SCC-9 cells. In addition, PKMYT1 was demonstrated to bind to CCNA2, and knocking down PKMYT1 resulted in inhibitory effects on cell proliferation, colony formation ability, migration, invasion and EMT by downregulating CCNA2 expression. PKMYT1 was observed to regulate the proliferation, migration and EMT of OSCC cells by targeting CCNA2, which may be used in the future to improve OSCC treatment.
Collapse
Affiliation(s)
- Ye Cai
- Department of Endodontics, Nanjing Stomatological Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210008, P.R. China
| | - Weidong Yang
- Department of Endodontics, Nanjing Stomatological Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210008, P.R. China
| |
Collapse
|
7
|
Posttreatment Magnetic Resonance Imaging Surveillance of Head and Neck Cancers. Magn Reson Imaging Clin N Am 2021; 30:109-120. [PMID: 34802574 DOI: 10.1016/j.mric.2021.06.018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Treatment strategies and recommended surveillance imaging differ for head and neck cancers depending on subsite and neoplasm type, and pose confusion for referring physicians and interpreting radiologists. The superior soft tissue resolution offered by magnetic resonance imaging is most useful in the surveillance of cancers with high propensities for intraorbital, intracranial, or perineural disease spread, which most commonly include those arising from the sinonasal cavities, nasopharynx, orbits, salivary glands, and the skin. This article discusses recommended surveillance protocoling and reviews treatment approaches, common posttreatment changes, and pearls for identifying disease recurrence in a subsite-based approach.
Collapse
|
8
|
Abdel Razek AAK, Elsebaie NA, Gamaleldin OA, AbdelKhalek A, Mukherji SK. Role of MR Imaging in Head and Neck Squamous Cell Carcinoma. Magn Reson Imaging Clin N Am 2021; 30:1-18. [PMID: 34802573 DOI: 10.1016/j.mric.2021.08.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Routine and advanced MR imaging sequences are used for locoregional spread, nodal, and distant staging of head and neck squamous cell carcinoma, aids treatment planning, predicts treatment response, differentiates recurrence for postradiation changes, and monitors patients after chemoradiotherapy.
Collapse
Affiliation(s)
| | - Nermeen A Elsebaie
- Department of Radiology, Alexandria Faculty of Medicine, Champollion Street, El-Khartoum Square, El Azareeta Medical Campus, Alexandria 21131, Egypt
| | - Omneya A Gamaleldin
- Department of Radiology, Alexandria Faculty of Medicine, Champollion Street, El-Khartoum Square, El Azareeta Medical Campus, Alexandria 21131, Egypt
| | - Amro AbdelKhalek
- Internship at Mansoura University Hospital, Mansoura Faculty of Medicine, 60 Elgomheryia Street, Mansoura 35512, Egypt
| | - Suresh K Mukherji
- Marian University, Head and Neck Radiology, ProScan Imaging, Carmel, IN, USA.
| |
Collapse
|
9
|
Development and Validation of an Autophagy-Related Signature for Head and Neck Squamous Cell Carcinoma. BIOMED RESEARCH INTERNATIONAL 2021; 2021:1028158. [PMID: 34423028 PMCID: PMC8373491 DOI: 10.1155/2021/1028158] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/27/2021] [Accepted: 07/23/2021] [Indexed: 11/18/2022]
Abstract
Introduction HNSCC is the sixth most frequent type of malignant carcinoma with a low prognosis rate. In addition, autophagy is important in cancer development and progression. The purpose of this study is to investigate the potential significance of ARGs in the diagnosis and treatment of HNSCC. Materials and Methods Expression data and clinical information of HNSCC samples were collected from the TCGA database, and a list of ARGs was obtained from the MSigDB. Then, we used R software to perform differential expression analysis and functional enrichment analysis. Further analysis was also performed to find out the survival-related ARGs in HNSCC, and two prognosis-related ARGs, FADD and NKX2-3, were selected to construct a prognosis prediction model. Moreover, some methods were applied to validate the prognosis prediction model. Finally, we used cell lines and clinical tissue samples of HNSCC to analyze the importance of FADD and NKX2-3. Results We screened a total of 38 differentially expressed ARGs, and enrichment analysis showed that these genes were mainly involved in autophagy. Then, we selected FADD and NKX2-3 to construct a prognosis model and the risk score calculated by the model was proved to be effective in predicting the survival of HNSCC patients. Additionally, significant differences of the clinicopathological parameters could also be observed in the risk scores and the expression of NKX2-3 and FADD. The expression of FADD and NKX2-3 in cell lines and HNSCC tissue samples also showed the same trends. Conclusions ARGs may be a potential biomarker for HNSCC prognosis, and targeted therapies for FADD and NKX2-3 are possible to be a new strategy of HNSCC treatment.
Collapse
|
10
|
Smith M, Bambach S, Selvaraj B, Ho ML. Zero-TE MRI: Potential Applications in the Oral Cavity and Oropharynx. Top Magn Reson Imaging 2021; 30:105-115. [PMID: 33828062 DOI: 10.1097/rmr.0000000000000279] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
ABSTRACT Zero-echo time (ZTE) magnetic resonance imaging (MRI) is the newest in a family of MRI pulse sequences that involve ultrafast sequence readouts, permitting visualization of short-T2 tissues such as cortical bone. Inherent sequence properties enable rapid, high-resolution, quiet, and artifact-resistant imaging. ZTE can be performed as part of a "one-stop-shop" MRI examination for comprehensive evaluation of head and neck pathology. As a potential alternative to computed tomography for bone imaging, this approach could help reduce patient exposure to ionizing radiation and improve radiology resource utilization. Because ZTE is not yet widely used clinically, it is important to understand the technical limitations and pitfalls for diagnosis. Imaging cases are presented to demonstrate potential applications of ZTE for imaging of oral cavity, oropharynx, and jaw anatomy and pathology in adult and pediatric patients. Emerging studies indicate promise for future clinical implementation based on synthetic computed tomography image generation, 3D printing, and interventional applications.
Collapse
Affiliation(s)
- Mark Smith
- Department of Radiology, Nationwide Children's Hospital, Columbus, OH
| | - Sven Bambach
- Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH
| | - Bhavani Selvaraj
- Department of Radiology, Nationwide Children's Hospital, Columbus, OH
| | - Mai-Lan Ho
- Department of Radiology, Nationwide Children's Hospital, Columbus, OH
| |
Collapse
|
11
|
Snyder V, Goyal LK, Bowers EMR, Kubik M, Kim S, Ferris RL, Johnson JT, Duvvuri U, Gooding WE, Branstetter BF, Rath TJ, Sridharan SS. PET/CT Poorly Predicts AJCC 8th Edition Pathologic Staging in HPV-Related Oropharyngeal Cancer. Laryngoscope 2021; 131:1535-1541. [PMID: 33428218 DOI: 10.1002/lary.29366] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2020] [Revised: 12/10/2020] [Accepted: 12/24/2020] [Indexed: 11/10/2022]
Abstract
OBJECTIVE The American Joint Committee on Cancer (AJCC) 8th edition introduced distinct clinical and pathological staging paradigms for human papilloma virus positive (HPV+) oropharyngeal squamous cell carcinoma (OPSCC). Treatment planning for OPSCC often utilizes positron emission tomography/computed tomography (PET/CT) to assess clinical stage. We hypothesize that PET/CT will accurately predict final pathologic AJCC 8th edition staging in patients with HPV+ OPSCC. METHODS All patients with primary HPV+ OPSCC with preoperative PET/CT who underwent transoral robotic surgery and neck dissection between 2011 and 2017 were identified. Data were collected via chart review. Two neuroradiologists performed blinded re-evaluation of all scans. Primary tumor size and cervical nodal disease characteristics were recorded and TNM staging was extrapolated. Cohen's kappa statistic was used to assess interrater reliability. Test for symmetry was performed to analyze discordance between radiologic and pathologic staging. RESULTS Forty-nine patients met inclusion criteria. Interrater reliability was substantial between radiologists for nodal (N) and overall staging (OS) (κ = 0.715 and 0.715). Radiologist A review resulted in identical OS for 67% of patients, overstaging for 31%, and understaging for 2%. Radiologist B review resulted in 61% identical OS, 39% overstaging, and 0% understaging. In misclassified cases, the test of symmetry shows strong bias toward overstaging N stage and OS (P < .001). Radiologic interpretation of extracapsular extension showed poor interrater reliability (κ = 0.403) and poor accuracy. CONCLUSION PET/CT predicts a higher nodal and overall stage than pathologic staging. PET/CT should not be relied upon for initial tumor staging, as increased FDG uptake is not specific for nodal metastases. PET/CT is shown to be a poor predictor of ECE. LEVEL OF EVIDENCE 4 Laryngoscope, 131:1535-1541, 2021.
Collapse
Affiliation(s)
- Vusala Snyder
- Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania, U.S.A
| | - Lindsey K Goyal
- Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania, U.S.A
| | - Eve M R Bowers
- Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania, U.S.A
| | - Mark Kubik
- Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania, U.S.A
| | - Seungwon Kim
- Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania, U.S.A
| | - Robert L Ferris
- Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania, U.S.A
| | - Jonas T Johnson
- Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania, U.S.A
| | - Umamaheswar Duvvuri
- Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania, U.S.A
| | - William E Gooding
- Department of Epidemiology and Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania, U.S.A
| | - Barton F Branstetter
- Department of Neuroradiology, University of Pittsburgh, Pittsburgh, Pennsylvania, U.S.A
| | | | - Shaum S Sridharan
- Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania, U.S.A
| |
Collapse
|
12
|
Zhang D, Tang D, Heng Y, Zhu XK, Zhou L, Tao L, Lu LM. Prognostic Impact of Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma Patients. Laryngoscope 2020; 131:E1249-E1255. [PMID: 33107987 DOI: 10.1002/lary.29196] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2020] [Revised: 09/13/2020] [Accepted: 10/08/2020] [Indexed: 01/06/2023]
Abstract
OBJECTIVES/HYPOTHESIS Tumor-infiltrating lymphocytes (TILs) has been shown to be associated with the prognosis of many tumors, yet few studies have investigated their roles in laryngeal squamous cell carcinoma (LSCC). We aim to investigate the prognostic values of tumor-infiltrating CD3+ /CD4+ /CD8+ /Foxp3+ T-cells and neutrophils in LSCC patients that received total or partial laryngectomy. STUDY DESIGN Retrospective case series of LSCC patients who underwent total or partial laryngectomy from 2013 to 2014 at Eye, Ear, Nose, and Throat Hospital of Fudan University. METHODS In our study, 41 tumor tissues from patients with LSCC were retrospectively assessed using immunohistochemistry for CD3+ /CD4+ /CD8+ /Foxp3+ T-cells and CD66b+ neutrophils. Overall survival (OS) and disease-free survival (DFS) were recorded using Kaplan-Meier methods. RESULTS Generally, patients with high density of TILs (CD3, CD4, CD8) showed improved OS or DFS. Specifically, high density of CD3+ TILs were associated with better OS, yet poorer OS and DFS for CD66b+ neutrophils. Patients with an Immunoscore of 0-1 experienced the worst OS and DFS, compared with Immunoscore 2-4 (P = .0111 for OS, P = .0391 for DFS). In Cox proportional hazards analysis adjusted for N stage and T stage, only stroma CD66b+ neutrophils densities were able to predict OS, with odds ratios of 4.819 (95% confidence interval [CI] 1.149-20.206; P = .032*), and DFS 2.888 (95% CI 1.043-7.997; P = .041*). CONCLUSIONS The density of TILs and CD66b+ neutrophils may help predict the prognosis of patients with LSCC after surgery. LEVEL OF EVIDENCE 3 Laryngoscope, 131:E1249-E1255, 2021.
Collapse
Affiliation(s)
- Duo Zhang
- Department of Otolaryngology-HNS, Eye, Ear, Nose and Throat Hospital, Shanghai Key Clinical Disciplines of Otorhinolaryngology, Fudan University School of Medicine, Shanghai, People's Republic of China.,Department of Pudong Hospital, Fudan University School of Medicine, Shanghai, People's Republic of China
| | - Di Tang
- Department of Otolaryngology-HNS, Eye, Ear, Nose and Throat Hospital, Shanghai Key Clinical Disciplines of Otorhinolaryngology, Fudan University School of Medicine, Shanghai, People's Republic of China.,Department of Pudong Hospital, Fudan University School of Medicine, Shanghai, People's Republic of China
| | - Yu Heng
- Department of Otolaryngology-HNS, Eye, Ear, Nose and Throat Hospital, Shanghai Key Clinical Disciplines of Otorhinolaryngology, Fudan University School of Medicine, Shanghai, People's Republic of China.,Department of Pudong Hospital, Fudan University School of Medicine, Shanghai, People's Republic of China
| | - Xiao-Ke Zhu
- Department of Otolaryngology-HNS, Eye, Ear, Nose and Throat Hospital, Shanghai Key Clinical Disciplines of Otorhinolaryngology, Fudan University School of Medicine, Shanghai, People's Republic of China.,Department of Pudong Hospital, Fudan University School of Medicine, Shanghai, People's Republic of China
| | - Liang Zhou
- Department of Otolaryngology-HNS, Eye, Ear, Nose and Throat Hospital, Shanghai Key Clinical Disciplines of Otorhinolaryngology, Fudan University School of Medicine, Shanghai, People's Republic of China.,Department of Pudong Hospital, Fudan University School of Medicine, Shanghai, People's Republic of China
| | - Lei Tao
- Department of Otolaryngology-HNS, Eye, Ear, Nose and Throat Hospital, Shanghai Key Clinical Disciplines of Otorhinolaryngology, Fudan University School of Medicine, Shanghai, People's Republic of China.,Department of Pudong Hospital, Fudan University School of Medicine, Shanghai, People's Republic of China
| | - Li-Ming Lu
- Shanghai Institute of Immunology, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China
| |
Collapse
|